DxTerity Diagnostics Inc and Caliper Life Sciences Inc have entered into a co-development and co-marketing strategic collaboration that will allow researchers to perform DxTerity’s NEATmultiplex diagnostic assays on Caliper’s LabChip Dx instrument platform minimizing sample processing time without compromising data quality. Caliper’s future LabChip Dx instruments will include specific diagnostic identification, scoring, and reporting software developed in collaboration with DxTerity.
DxTerity’s NEAT assays allow analysis of gene expression and detection of single nucleotide polymorphisms (SNPs) directly from blood or formalin-fixed paraffin embedded (FFPE) tissue samples, virtually eliminating complex sample preparation processes. Multiplex assays for up to 40 gene targets are routinely performed, delivering unique applications for clinical diagnostics and life science research. DxTerity’s lead clinical product in development is a blood screening test that measures a patient’s radiation exposure following a nuclear event, such as the recent disaster in Fukushima, Japan. The initial release of this product is scheduled for June of 2012. DxTerity is also developing low cost, blood-based cancer screening tests based upon the gene signature panels acquired from SourceMDx.
The LabChip Dx system is based on Caliper’s patented microfluidic separation technology, and enables high-throughput multiplex analysis for discovery and validation of nucleic acid and protein biomarkers. The LabChip Dx system uses minimal sample volumes and enables automated sample processing and analysis, providing a robust and cost-effective platform that is achieving a high rate of adoption among diagnostic laboratories around the world.
Source: Caliper Life Sciences Inc
